Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Empagliflozin-Based Quadruple Oral Therapy for Type 2 Diabetes: A Prospective Cohort Study Publisher Pubmed



Moosaie F1, 2, 3 ; Abedinzadeh S1 ; Rabizadeh S1 ; Daneshvar K1, 4 ; Noorafrooz M1 ; Mojtahedi FA1 ; Deravi N1, 5 ; Fatemi Abhari SM6 ; Ramezani A1 ; Meysamie A7 ; Hajibabaei M3 ; Reyhan SK1 ; Abbaszadeh M1 ; Nakhjavani M1 Show All Authors
Authors
  1. Moosaie F1, 2, 3
  2. Abedinzadeh S1
  3. Rabizadeh S1
  4. Daneshvar K1, 4
  5. Noorafrooz M1
  6. Mojtahedi FA1
  7. Deravi N1, 5
  8. Fatemi Abhari SM6
  9. Ramezani A1
  10. Meysamie A7
  11. Hajibabaei M3
  12. Reyhan SK1
  13. Abbaszadeh M1
  14. Nakhjavani M1
  15. Esteghamati A1
Show Affiliations
Authors Affiliations
  1. 1. Endocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, P.O. Box: 13145-784, Tehran, Iran
  2. 2. International Surgical Research Association (ISRA), Universal Scientific Education and Research Network (USERN), Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Psychosomatic Medicine Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Department of Pediatrics, Imam Ali Hospital, Alborz University of Medical Sciences, Karaj, Iran
  7. 7. Department of Community Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Scientific Reports Published:2025


Abstract

The management of Type-2 Diabetes Mellitus (T2DM) remains challenging in cases of poor glycemic control despite triple Oral Hypoglycemic Agent (OHA) therapy. This prospective cohort study aimed to assess the effectiveness of Empagliflozin as part of a quadruple OHA regimen over a 7-year follow-up period in 575 adult patients with uncontrolled T2DM on a triple OHA regimen and who were unwilling to initiate insulin therapy. Overall, 92.5% of patients achieved their target HbA1c levels. Significant reductions were observed in all glycemic parameters after 68 months (p < 0.001). Weight and BMI significantly decreased, whereas waist circumference remained unchanged. Lipid profiles showed significant improvements in total cholesterol, LDL, and triglycerides, while HDL levels did not change significantly. Blood pressure trends revealed significant reductions in both diastolic blood pressure (DBP) and mean arterial pressure (MAP), though systolic blood pressure (SBP) remained relatively stable. Our study indicates that adding empagliflozin to a drug regimen consisting of multiple OHAs can effectively control glycemia in T2DM patients with more pronounced target achievement (< 7%) and HbA1c reduction along with improvement in cardiometabolic parameters, suggesting its potential as a promising alternative for long-term glycemic management. © The Author(s) 2025.